Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluation of Seegene Allplex Respiratory Panel 1 kit for the detection of influenza virus and human respiratory syncytial virus

Laura Gimferrer, Cristina Andrés, Ariadna Rando, Maria Piñana, Maria Gema Codina, Maria del Carmen Martin, Francisco Fuentes, Susana Rubio, Pilar Alcubilla, Tomàs Pumarola⁎, Andrés Antón

Virology Unit, Microbiology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron, 119-129, Barcelona, Spain

ARTICLE INFO

Keywords:
Influenza viruses
Human respiratory syncytial virus
Real-time RT-PCR
Epidemiology

ABSTRACT

Background: Influenza (FLUV) and human respiratory syncytial (HRSV) viruses are etiological agents of respiratory infections that cause a significant morbidity and mortality worldwide. A rapid and accurate diagnosis of these respiratory viruses is essential for an appropriate patient management. Molecular tests are the best detection option due to their high sensitivity and specificity. Seegene’s Allplex™ Respiratory Panel 1 (Allplex RP1) is a real-time one-step RT-PCR assay for the simultaneous detection of FLUAV, FLUBV, HRSV-A and HRSV-B. In addition, it allows the determination of FLUAV subtype (H1, H3 and H1pdm09).

Objectives: This study aims to evaluate Allplex RP1 as a rapid molecular test for the detection of FLUAV, FLUBV, HRSV-A and HRSV-B viruses.

Study design: The Allplex RP1 assay will be compared with other two commercial molecular assays, Prodesse ProFlu+ and ProFAST+ (Hologic, Madison, WI, USA), and GeneXpert Flu/RSV XC (Cepheid, USA).

Results: Allplex RP1, ProFlu+ and GeneXpert tests showed 95%, 91% and 96% of accuracy; and 94%, 88% and 95% of sensitivity, respectively. Moreover, Allplex RP1 showed a FLUAV subtype sensitivity of 91% and 88% for FLUAV-H1pdm09 and FLUAV-H3 respectively, and ProFAST+ assay showed sensitivities of 100% for both targets. The three assays showed a 100% of specificity and PPV, while the NPV were 84%, 73% and 86% for Allplex RP1, Prodesse and GeneXpert, respectively.

Conclusions: In this study, Seegene’s Allplex RP1 assay showed to be highly sensitive, specific, and suitable for detection of FLUV and HRSV, including FLUAV subtyping. In addition, it is also a hands-on-time saving assay due to the automated nucleic acid extraction and PCR setup.

1. Background

Acute respiratory infections (ARI) represent a major threat to public health. Influenza virus (FLUV) and human respiratory syncytial virus (HRSV) respiratory infections are responsible for significant morbidity and mortality in both pediatric and adult population worldwide [1,2]. Seasonal FLUV has been estimated to affect 5–10% of the world’s population [3] and by the age of two, practically all children are estimated to have been infected at least once with HRSV [4]. An early identification of the causative pathogen is essential for a prompt and appropriate patient management [5]. Furthermore, it minimizes the patient hospitalization stay and risk of complications, as well as it aims to establish a rapid implementation of isolation and control measures reducing the nosocomial transmission risk [6]. Microbiological tests are needed for a precise and rapid identification of the causative agents. Among them, techniques such as viral culture isolation and antigen-based assays have been widely used in the past. However, these techniques have low and widely variable sensitivity and specificity. Moreover, they are time-consuming and labour-intensive [7]. Therefore, molecular tests are nowadays considered the best detection choice as they have demonstrated to be the most sensitive and specific techniques. In addition, the use of multiplex PCR-based methods enables a rapid and accurate identification of multiple targets in the same reaction [8].

2. Objectives

Allplex™ Respiratory Panel 1 (Allplex RP1) (Seegene INC., Seoul,
Within the evaluation. For the hospital routine testing, specimens were processed during the 2014-2015 season, which were submitted to the laboratory for routine testing. The Allplex Respiratory Panel 1 kit has been evaluated, by comparing it with Prodesse Flu/RSV, FLUAV-H1pdm09 and FLUAV-H3] assays depending on the clinical needing. In case of FLUV or FLUBV, the diagnostic value of the HRSV genetic group (A or B). Then, samples were kept in aliquots at −80 °C until their use for the clinical evaluation.

The evaluation was performed using a total of 316 samples that included 77 negative specimens for any respiratory virus (including Adenovirus, FLUAV, FLUBV, Parainfluenza virus, Rhinovirus, HRSV-A, HRSV-B, Bocavirus, Metapneumovirus, Coronavirus, Enterovirus) and 239 laboratory-confirmed specimens for the tested targets: 59 FLUAV-H1pdm09, 43 FLUAV-H3, 45 FLUBV, 50 HRSV-A and 42 HRSV-B.

### Table 1

| Pathogens | No. of positive specimens tested | Performances | Allplex™ Respiratory Panel 1 | Prodesse ProFlu+/ProFAST+ | GeneXpert Flu/RSV XC |
|-----------|---------------------------------|--------------|-----------------------------|---------------------------|----------------------|
| General   | 316                             | accuracy%    | 95.3 92.3–97.3              | 91.1 87.5–94.0            | 95.9 93.1–97.8       |
|           |                                 | sensitivity% | 93.7 89.9–96.5              | 88.3 83.5–92.1            | 94.6 90.9–97.1       |
|           |                                 | specificity% | 100.0 95.3–100.0            | 100.0 95.3–100.0          | 100.0 95.3–100.0     |
|           |                                 | PPV%         | 100.0 –                     | 73.3 66.0–79.6            | 85.6 77.7–90.9       |
|           |                                 | NPV%         | 82.7 75.9–89.3              | 88.3 82.6–92.6            | 95.0 90.7–97.7       |
| Influenza A | 102                             | sensitivity% | 90.2 [91.5; 87.7–95.2]     | 79.4 [100.0; 71.0–81.9]  | 91.2 83.9–95.5       |
|           |                                 | subtype sensitivity% | 88.4 [81.3–97.2; 74.9–96.1] |                           |                      |
|           |                                 | specificity% | 100.0 95.3–100.0            | 100.0 95.3–100.0          | 100.0 95.3–100.0     |
|           |                                 | PPV%         | 100.0 –                     | 100.0 –                  | 100.0 –              |
|           |                                 | NPV%         | 88.5 81.0–93.3              | 78.6 71.5–84.3            | 89.5 82.1–94.1       |
| Influenza B | 45                              | accuracy%    | 95.9 91.0–98.7              | 95.1 89.6–98.2            | 96.7 91.8–99.1       |
|           |                                 | sensitivity% | 88.9 76.0–96.3              | 86.7 73.2–95.0            | 91.1 78.6–97.5       |
|           |                                 | specificity% | 100.0 95.3–100.0            | 100.0 95.3–100.0          | 100.0 95.3–100.0     |
|           |                                 | PPV%         | 100.0 –                     | 100.0 –                  | 100.0 –              |
|           |                                 | NPV%         | 93.9 87.1–97.2              | 92.8 85.9–96.4            | 95.1 88.3–98.0       |
| HRSV-A    | 50                              | accuracy%    | 100.0 97.1–100.0            | 99.2 95.7–100.0           | 100.0 97.1–100.0     |
|           |                                 | sensitivity% | 100.0 92.9–100.0            | 98.0 89.3–100.0           | 100.0 92.9–100.0     |
|           |                                 | specificity% | 100.0 95.3–100.0            | 100.0 95.3–100.0          | 100.0 95.3–100.0     |
|           |                                 | PPV%         | 100.0 –                     | 100.0 –                  | 100.0 –              |
|           |                                 | NPV%         | 100.0 –                     | 98.7 91.7–99.8            | 100.0 –              |
| HRSV-B    | 42                              | accuracy%    | 100.0 97.0–100.0            | 100.0 97.0–100.0          | 100.0 97.0–100.0     |
|           |                                 | sensitivity% | 100.0 91.6–100.0            | 100.0 91.6–100.0          | 100.0 91.6–100.0     |
|           |                                 | specificity% | 100.0 95.3–100.0            | 100.0 95.3–100.0          | 100.0 95.3–100.0     |
|           |                                 | PPV%         | 100.0 –                     | 100.0 –                  | 100.0 –              |
|           |                                 | NPV%         | 100.0 –                     | 100.0 –                  | 100.0 –              |

Abbreviations: CI = confidence interval, PPV = positive predictive value, NPV = negative predictive value.
Table 2

Results of the reproducibility evaluation for the eight analyzed panels. Test performed during 5 days with two repeats for each panel.

| Panels        | Ct mean | % CV |
|---------------|---------|------|
| FLUAV-H1 pdm09| High     | 24.2 | 3.3 |
|               | Low      | 34.2 | 1.8 |
| FLUAV-H3      | High     | 27.5 | 3.9 |
|               | Low      | 33.9 | 7.2 |
| FLUBV         | High     | 26.6 | 6.5 |
|               | Low      | 34.4 | 8.9 |
| HRSV          | High     | 30.7 | 11.2|
|               | Low      | 36.2 | 5.6 |

Abbreviations: CV = variance coefficient.

4. Results

Results obtained by the three detection methods and their comparison are summarized in Table 1. Allplex RP1 test showed 95.3% of accuracy having correctly classified 301 out of 316 samples, 224 as true positive and 77 as true negative. On the other hand, ProFlu + showed 91.1% of accuracy having correctly classified 288 out of 316 samples, 211 as true positive and 77 as true negative. Finally, GeneXpert test showed a general accuracy of 95.9% having correctly classified 303 out of 316 samples, 226 as true positive and 77 true negatives. Regarding the sensitivity of all three assays, Allplex RP1 assay showed a general sensitivity of 93.7% (90.2% for FLUAV, 88.9% for FLUBV, 100.0% for HRSV-A and 100.0% for HRSV-B). ProFlu + assay showed a general sensitivity of 88.3% (79.4% for FLUAV, 86.7% for FLUBV, 98.0% for HRV-A and 100.0% for HRSV-B). Finally, GeneXpert assay showed a general sensitivity of 94.6% (91.2% for FLUAV, 91.1% for FLUBV and 100.0% for both HRSV groups). In addition, Allplex RP1 and ProFAST + sensitivities were also compared by FLUAV subtype. Whereas Allplex RP1 showed a sensitivity of 91.5% and 88.4% for FLUAV-H1 pdm09 and FLUAV-H3 respectively, ProFAST+ assay showed sensitivities of 100.0% for both targets. Regarding the specificity, the three assays showed values of 100.0%. The PPV was 100.0% for the three assays, while the NPV were 83.7%, 73.3% and 85.6% for Allplex RP1, Prodesse and GeneXpert, respectively. Moreover, 60 samples showed invalid results for at least one assay (Allplex RP1: 46 invalid samples, Prodesse: 8 invalid samples and GeneXpert: 10 invalid samples), which could also not be re-tested due to insufficient sample volume, and therefore were not finally included in the statistical analysis. Regarding the repeatability analysis, variance coefficient (CV) ranges from a minimum of 1.8 to a maximum of 11.2 (Table 2).

5. Discussion

Molecular real-time PCR-based methods have been increasingly used for the detection of both FLUV and HRSV. It is well known that NA amplification tests are thought to be superior in many aspects as sensitivity or specificity among other parameters compared to conventional diagnostic techniques such as cell culture or antigen based assays [9,10]. However, in addition to the variability of these parameters between the different commercial kits available in the market, the need for the automation of extraction and PCR setup is also demanded to minimize the user-related biased [11]. In this study, the novel Allplex RP1 assay was compared with ProFlu + and GeneXpert assays for the detection of FLUV and HRSV, and with ProFAST + to determine the FLUAV subtype.

In terms of sensitivity, accuracy and NPV GeneXpert assay exhibited the highest results followed by Allplex RP1 assay. Moreover, the three studied assays showed excellent specificity and PPV values. An important characteristic of Allplex RP1 to be highlighted is that it works detecting two different targets of FLUV in a single reaction allowing to determine FLUAV subtype and then improving its detection. Though

ProFAST + assay showed highest sensitivity values than Allplex RP1 assay for FLUAV subtyping, Hologic assay required to perform an additional reaction increasing the final test cost. In addition, it is important to consider that in the case of Hologic only the subtyping of those samples that were positive for FLUAV for the ProFlu + test was then tested by ProFAST+. Moreover, Allplex RP1 in contrast to both ProFlu + and GeneXpert also provided information regarding the genetic group of HRSV, distinguishing between group A and group B. The availability of an assay that provides all these information is an excellent option to be used in the laboratory since it reports relevant epidemiological interest information [12]. Nonetheless, in this study the validation parameters for FLUAV-H1 could not be determined because there was no availability of seasonal FLUAV-H1 laboratory-confirmed samples. It is well-known that seasonal FLUAV-H1 does not circulate worldwide since the 2009–2010 season but a future circulation of this FLUAV subtyped cannot be discarded in a near future. The availability to detect this target, particularly in a commercial diagnostic method, might help to monitor the re-emergence of this FLUV subtype in the community.

Regarding the repeatability of the technique, the maximum percentage of CV found for Allplex RP1 was 11.2%, less than recommended (15% of the CV) by The Food and Drug Administration Guidance for industry (May, 2001) [13].

In case of laboratories with a high number of specimens to be tested, Seegene’s Allplex RP1 in MICROLAB Nimbus IVD have shown to be very useful as it processed up to 48 samples in a single run that included NA extraction and PCR setup. The whole procedure from NA extraction to results interpretation lasted for less than 5 h per run and needed only 10 min of hands-on time work. The automated process and the minimum hands-on time must be remarked as it can be used in a high-throughput laboratory workflow, minimizing human error risk and NA contaminations, improving the quality control and reducing the laboratory-related costs. In addition, the data interpretation software (Seegene Viewer) is optimized for multiplex assays and detects in a single channel multiple Ct and fluorophores values providing a semi-quantitative information and also minimizing human error, which could occur with higher probability in the interpretation of fluorescent curves in the case of Hologic’s assay.

The data of the present study showed that Allplex RP1 is a highly sensitive, specific, and suitable assay for FLUV and HRSV detection and typing, providing not only relevant information for clinical patient management but also valuable data for epidemiological purposes. The chance of sample handling automation, from NA extraction to PCR setup, improves its suitability for the routine analysis.

Acknowledgements

This work was partially supported by Plan Nacional de I + D + i 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015) – co-financed by European Development Regional Fund “A way to achieve Europe” ERDF. The authors declare no conflicts of interest.

References

[1] L. Gimferrer, M. Campins, M.G. Codina, F. Martín MeC. Fuentes, J. Esperalba, et al., Molecular epidemiology and molecular characterization of respiratory syncytial viruses at a tertiary care university hospital in Catalonia (Spain) during the 2013–2014 season, J. Clin. Virol. 66 (2015) 27–32.
[2] S. Saxena, D. Singh, A. Zia, J. Umzao, N. Srivastava, A. Pandey, et al., Clinical characterization of influenza A and human respiratory syncytial virus among patients with influenza like illness, J. Med. Virol. 89 (1) (2017) 49–54.
[3] (Seasonal) WHOI, Fact sheet No. 211, 2009.
[4] J. Tatababai, C. Prifert, J. Pfeil, J. Grulich-Henn, P. Schnitzler, Novel respiratory syncytial virus (RSV) genotype ON1 predominates in Germany during winter season 2012–13, PLoS One 9 (10) (2014) e109191.
[5] J.C. Hurtado, M.M. Mosquera, E. de Lazzari, E. Martínez, N. Torner, R. Isanta, et al., Evaluation of a new, rapid, simple test for the detection of influenza virus, BMC Infect. Dis. 15 (2015) 44.

[6] S. Pillet, M. Lardeux, J. Dina, F. Grattard, P. Verhoeven, J. Le Golf, et al., Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections, PLoS One 8 (8) (2013) e72174.

[7] J. Liu, L. Yao, F. Zhai, Y. Chen, J. Lei, Z. Bi, et al., Development and application of a triplex real-time PCR assay for the simultaneous detection of avian influenza virus subtype H5, H7 and H9, J. Virol. Methods 252 (2017) 49–56.

[8] S.Y. Shin, K.C. Kwon, J.W. Park, J.M. Kim, S.H. Koo, Evaluation of the Seeplex® Meningitis ACE Detection kit for the detection of 12 common bacterial and viral pathogens of acute meningitis, Ann. Lab. Med. 32 (1) (2012) 44–49.

[9] Y.G. Kim, S.G. Yun, M.Y. Kim, K. Park, C.H. Cho, S.Y. Yoon, et al., Comparison between saliva and nasopharyngeal swab specimens for the detection of respiratory viruses by multiplex reverse transcription polymerase chain reaction, J. Clin. Microbiol. 55 (1) (2016) 226–233.

[10] D.H. Ko, H.S. Kim, J. Hyun, J.S. Kim, K.U. Park, W. Song, Comparison of the Luminex xTAG respiratory viral panel fast v2 assay with anyplex II RV16 detection kit and AdvanSure RV real-Time RT-PCR assay for the detection of respiratory viruses, Ann. Lab. Med. 37 (5) (2017) 408–414.

[11] Y. Kim, M.S. Han, J. Kim, A. Kwon, K.A. Lee, Evaluation of three automated nucleic acid extraction systems for identification of respiratory viruses in clinical specimens by multiplex real-time PCR, BioMed. Res. Int. 2014 (2014) 430650.

[12] A. Eshaghi, V.R. Duvvuri, R. Iai, J.T. Nadarajah, A. Li, S.N. Patel, et al., Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication, PLoS One 7 (3) (2012) e32807.

[13] F.D.A, Guidance for Industry: Bioanalytical Method Validation, (2001).